SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 0.00 |
| Enterprise Value ($M) | -0.65 |
| Book Value ($M) | -18.88 |
| Book Value / Share | -1.43 |
| Price / Book | 0.00 |
| NCAV ($M) | -62.05 |
| NCAV / Share | -4.70 |
| Price / NCAV | 0.00 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -0.03 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.15 |
| Current Ratio | 0.15 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.82 |
| Assets | 44.00 |
| Liabilities | 62.87 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Radcliffe Capital Management, L.P. | 0.00 | -100.00 | |
| 13G/A | Sandia Investment Management LP | 0.76 | -75.00 | |
| 13G/A | Saba Capital Management, L.P. | 0.00 | -100.00 | |
| 13G | Spring Creek Capital Llc | 7.68 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1 | 1 | 100.00 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| PTN – Palatin Technologies, Inc. | SCPX – Scorpius Holdings, Inc. |
| TOVX – Theriva Biologics, Inc. | VNRX – VolitionRx Limited |
| XTNT – Xtant Medical Holdings, Inc. |
Financial data and stock pages provided by
Fintel.io